| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a715e3cc143ff405ac2730301657d10 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277 |
| filingDate |
2018-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5406eebf6c5963c95053d96d32d7d31b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_346c99e4b1eca6fee2177b2e2f57e765 |
| publicationDate |
2020-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2020004960-A |
| titleOfInvention |
ASSOCIATION OF ASSETS TO TREAT PROSTATE CANCER. |
| abstract |
The invention relates to a pharmaceutical combination of an androgen receptor signaling pathway inhibitor and a p38 inhibitor for use in the treatment of prostate cancer in individuals in which the prostate tumor cells express the receptor protein. variant AR-V7 or to prevent the emergence of resistance in patients suffering from prostate cancer treated with an inhibitor of the androgen receptor signaling pathway. The invention also relates to a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient. The invention also relates to the use of a p38 inhibitor to restore sensitivity to androgen deprivation therapy (ADT) in patients suffering from prostate cancers that have acquired resistance to ADT after treatment with a p38 inhibitor. androgen receptor signaling pathway and wherein prostate tumor cells express the AR-V7 variant androgen receptor protein. |
| priorityDate |
2017-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |